Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
Nurix Therapeutics announced a global collaboration with Roche to co-develop and co-commercialize bexobrutideg, a potential best-in-class BTK degrader. Nurix will receive a $700 million upfront payment and is eligible for up to $2.3 billion in additional development, regulatory, and sales milestones. The partnership covers malignant hematology, immunology, and neurology, with Roche handling commercialization outside the U.S.
Key figures
- Deal Value Usd
- 2300000000
- Upfront payment
- 700000000
- Us profit share
- 50/50
- Total milestones
- 2300000000
- Ex us royalty range
- low- to high-teens
- Development cost share nurix
- 40%
- Development cost share roche
- 60%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.